Physician
Internal Medicine
Dr. Paul G. Corn, MD
|
|
Give Review
Paul Corn is an expert in the field of Internal Medicine. He researched medicine at Georgetown University School of Medicine. Georgetown University School of Medicine is ranked 49/84 in Research/PrimaryCare. Paul Corn is a published doctor. He has 61 publications published. The most current publication "Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia." Doctor Paul G. Corn, MD is registered with Medicare and accepts Medicare payments.
Publications
- Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
- Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Facto...
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
- Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer.
- MET abnormalities in patients with genitourinary Malignancies and outcomes with c-MET inhibitors.
- Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma.
- Prostate Cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study.
- Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate Cancer.
- Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort.
- The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia Cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
- Src signaling pathways in prostate Cancer.
- Targeting fibroblast growth factor pathways in prostate Cancer.
- Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules.
- mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell Cancer: management, predictors, and outcomes.
- Outcomes of patients with metastatic clear-Cell renal Cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.
- Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study.
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
- PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation The...
- The role of HGF/c-Met signaling in prostate Cancer progression and c-Met inhibitors in clinical trials.
- Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer.
- Using methylation analysis to assess tumor heterogeneity in familial breast Cancer.
- MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal Cancer cell lines.
- Methylation marks the path for biomarker development in breast Cancer research.
- Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal Cell carcinoma.
- Inhibition of RNA-dependent protein kinase (PKR) leads to Cancer cell death and increases chemosensitivity.
- Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal Cancer tumorigenesis.
- Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma: defining the pancreatic Cancer [corrected] epigenome.
- Hypoxic regulation of mRNA expression.
- Hypoxic regulation of miR-210: shrinking targets expand HIF-1's influence.
- Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage.
- Reactivation of p53 function with a demethylating agent.
- Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects Cells from c-Myc-induced apoptosis.
- Caspase 10 levels are increased following DNA damage in a p53-dependent manner.
- Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
- Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer.
- Identification of a novel prostate Cancer biomarker, caveolin-1: Implications and potential clinical benefit.
- Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate Cancer.
- Derangement of growth and differentiation control in oncogenesis.
- Frequent hypermethylation of the 5'' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung Cancer.
- Role of the ubiquitin proteasome system in renal Cell carcinoma.
- Amplification status of capsule genes in Haemophilus influenzae type b clinical isolates.
- Restoration of a phosphaturic response to parathyroid hormone in the immature rat.
- Genes involved in Haemophilus influenzae type b capsule expression are frequently amplified.
- Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia.
- Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human Cancers.
- Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.
- Epigenetic inactivation of LKB1 in primary Tumors associated with the Peutz-Jeghers syndrome.
- E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia.
- p14ARF silencing by promoter hypermethylation mediates abnormal intraCellular localization of MDM2.
- A gene hypermethylation profile of human Cancer.
- Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small Cell lung carcinoma.
- Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenoCarcinoma.
- Outcome of patients with metastatic renal Cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
- Dasatinib inhibits both osteoclast activation and prostate Cancer PC-3-cell-induced osteoclast formation.
- Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal Cell carcinoma: clinical and biomarker an...
- Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal Cell carcinoma.
- 5-Aza-2''-deoxycytidine sensitizes busulfan-resistant myeloid leukemia Cells by regulating expression of genes involved in Cell cycle checkpoint and apoptosis.
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
Schools
Georgetown Univ Sch Of Med
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Education
-
Johns Hopkins University -
University of Chicago -
Georgetown University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1629164314 | |
| NPPES Provider LastName | CORN | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1215.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 104.0 | |
| Percent Opioid Claims | 8.56 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629164314 |
| Last Name Of The Provider | CORN |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Glenda L. Coleman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margaret B. Row, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steffanie R. Campbell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul W. English, MD |
|
|
Dr. Mariana Chavez MacGregor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Hui, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Marieberta Vidal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer Wheler, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nicholas E. Papadopoulos, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Bryan T. Hennessy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joanna H. Queen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zhouwen Tang, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sonali N. Thosani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adnan Rafiq, MD
This Doctor is OpenDoctor Recommended.
|